-
Novartis's first complement factor B inhibitor iptacopan has been certified by the British Innovation Passport
Time of Update: 2021-11-15
Novartis recently announced that the British Medicines and Healthcare Products Regulatory Agency (MHRA), the National Institute of Health and Clinical Optimization (NICE), and the Scottish Medical Federation (SMC) have awarded oral therapy iptacopan (LNP023) for the treatment of C3 glomeruli "Innovation Passport" qualification for disease (C3G) .
-
What is the reason why distributors such as Sinopharm, China Resources and Shanghai Pharmaceuticals are so good in hospitals?
Time of Update: 2021-11-15
Therefore, data shows that only giant companies such as Sinopharm, Shanghai Pharmaceuticals, China Resources Pharmaceuticals, and Jointown are eligible to be listed on the candidate list of medical consumables distributors for large hospitals .
-
The scale of the domestic pharmaceutical packaging machinery and equipment market exceeds 20 billion, and the high-end market needs to be tapped
Time of Update: 2021-11-15
. In this context, China's pharmaceutical packaging machinery and equipment industry still needs to make continuous efforts to develop toward a more intelligent and informatized direction to help improve the level of China's pharmaceutical packaging, thereby enhancing the competitiveness of China's pharmaceutical products in the international market .
-
The ophthalmology medical market continues to improve, and the performance of related companies continues to improve
Time of Update: 2021-11-15
Among them, the net profit in the third quarter was 888 million yuan, a year-on-year increase of 2.
On October 24, the 2021 third quarter report of Guangzheng Ophthalmology showed that the company's main operating income was 779 million yuan, a year-on-year increase of 25.
-
Teriplizumab is expected to be approved in the U.S. in April next year
Time of Update: 2021-11-15
On October 31, Junshi Biotech announced that the FDA has accepted and granted priority review for the Biological Products License (BLA) for two nasopharyngeal cancer indications for teriprizumab.
-
The world's first basal insulin GLP-1RA injection Novo is approved in China
Time of Update: 2021-11-15
Novoyi® is the world's first basal insulin glucagon-like peptide-1 receptor agonist (GLP-1RA) injection, which is composed of insulin deglubber and liraglutide [2], a breakthrough integration of deglu The two-component advantages of insulin and liraglutide, complementary mechanisms, multi-targeted action on multiple pathophysiological mechanisms of type 2 diabetes[3],[4],[5], once a day, powerful control of blood sugar throughout the day , The glycated hemoglobin (HbA1c) compliance rate is as high as 89.
-
As China vigorously promotes the development of pharmaceutical innovation, multinational pharmaceutical companies are accelerating reforms
Time of Update: 2021-11-15
Based on the above, the industry believes that behind the drastic reforms of multinational pharmaceutical companies, in addition to being affected by the implementation of China's pharmaceutical industry policies in recent years, more importantly, the trend of the Chinese market environment is gradually shifting from generic drugs to innovation .
-
From November 1st, many traditional Chinese medicine products have been included in the scope of medical insurance payment
Time of Update: 2021-11-15
As Chinese medicine formula granules and Chinese medicine decoction pieces have been included in the scope of national and even local medical insurance reimbursements, the industry believes that it will have a huge impact on the Chinese medicine market .
-
The development of the pharmaceutical e-commerce market continues to improve, and online pharmaceutical sales of pharmaceutical companies have increased significantly
Time of Update: 2021-11-15
The industry believes that the substantial increase in Pien Tze Huang's net profit is a successful case of deepening cooperation between pharmaceutical companies, platforms, and end users to build a mature online sales network .
-
On the evening of October 26, it was announced that a number of pharmaceutical companies disclosed their three quarterly reports, and one company released an annual performance forecast
Time of Update: 2021-11-15
62%; non-recurring gains and losses attributable to shareholders of listed companies were deducted The net profit of 905 million yuan, a year-on-year increase of 19.
On the same day, the third quarter report disclosed by Liuyao shares showed that the company achieved operating income of 12.
-
Mixed joys and sorrows!
Time of Update: 2021-11-15
The total MADRS score of the patients who received 3 mg/day showed improvement in the 6th week, but it did not reach statistical significance compared with the control group .
-
The reshuffle of the pharmaceutical retail market has intensified, and a group of pharmacies have left the market sadly!
Time of Update: 2021-11-15
In addition to Guangdong Province, Shaanxi Province, Henan Province, Sichuan Province, Liaoning Province, Yunnan Province, Jiangsu Province and other places have also issued announcements on the cancellation of drug business licenses this year, and a large number of pharmacies are accelerating their withdrawal from the market.
-
Recently, the price of Chinese medicinal materials has generally risen. How will it affect related listed companies?
Time of Update: 2021-11-15
Regarding the increase in the price of raw materials, Tasly responded that the company has its own GAP planting base, and Panax notoginseng also has a strategic reserve of medicinal resources, which can reduce the impact of medicinal material price fluctuations on cost procurement .
-
Junshi Biological Appoints Vice President of Medical Sciences, worked in FDA for nearly 20 years
Time of Update: 2021-11-15
Maher worked in the US Food and Drug Administration (FDA) for nearly 20 years, serving as a clinical reviewer of the Office of Oncology Products, and a clinical review team of the Office of Cell, Tissue and Gene Therapy of the Center for Biologics Evaluation and Research (CBER) Chief, the clinical review team leader of the Blood and Tumor Products Office of the Center for Drug Evaluation and Research (CDER) .
-
This kind of Chinese medicine companies paid attention to the new national policy on November 1st!
Time of Update: 2021-11-15
According to the requirements of the "Notice", from November 1, 2021, The Chinese medicine formula granule varieties are subject to record management, and they need to be filed with the State Food and Drug Administration to obtain a record number before they are put on the market .
-
Dongyang Sun Pharmaceutical "Insulin Glargine" Approved for Listing
Time of Update: 2021-11-15
cn/v5/home/)In the sixth round of centralized insulin procurement of the list announced in September, the products included are all second- and third-generation insulins, grouped by quick-acting, basic and premix .
-
Major pharmaceutical companies have expanded their production capacity, and the demand for pharmaceutical equipment may continue to increase
Time of Update: 2021-11-15
For example, in order to help pharmaceutical companies improve production efficiency and further ensure drug quality, many companies have developed numerous intelligent and fully automatic equipment and production lines, which have also been widely used in the pharmaceutical production process .
-
A number of blockbuster new drugs have been approved for clinical use, and the R&D capabilities of local pharmaceutical companies have greatly improved
Time of Update: 2021-11-14
As of October 29, 2021, data from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration show that a total of 5670 clinical trial applications have passed "implicit permission .
According to data, in 2020, the Center for Drug Evaluation has approved 1,435 IND (New Drug Clinical Trial) applications, an increase of 54.
-
Announcement of the National Medical Products Administration on the addition of children's drug information to the instructions for haloperidol tablets and other varieties (No. 75 of 2021)
Time of Update: 2021-11-14
Recommendations for revisions to drug inserts of fluoxetine oral preparations National Food and Drug Administration May 28, 2021 Announcement No.
-
AstraZeneca sells two COPD drugs for $270 million
Time of Update: 2021-11-14
Eklira is a long-acting muscarinic antagonist (LAMA), which was approved for marketing in the European Union and the United States in 2012 .
